Thymosin alpha-1 sits in an unusual category: a peptide with genuine regulatory approvals abroad, decades of trials, and a recent large, well-conducted study that did not support one of its main proposed uses.
Overview
Thymosin alpha-1 (marketed as thymalfasin) has a far more developed evidence base than most peptides discussed alongside it — and the most rigorous trial ever run on it was negative. It has been approved in more than 35 countries for hepatitis B and C and as an immune stimulant and vaccine adjuvant, but it is not FDA-approved in the United States. In 2025 a multicentre phase 3 trial of 1,106 adults with sepsis found no reduction in 28-day mortality. Anyone reading "clinically validated immune peptide" should hold both facts at once.
Where it is approved, and for what
Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha, produced by the thymus, acting largely through Toll-like receptor signalling on dendritic cells and T-cell maturation. Allan Goldstein — who first isolated it — described its clinical position in a 2009 review in Expert Opinion on Biological Therapy: it was approved in over 35 countries for the treatment of hepatitis B and C and as an immune stimulant and adjuvant, with late-stage testing then under way in the US and Europe for hepatitis C and stage IV melanoma (PubMed 19392576).
Two things follow. Approval in 35 countries is a meaningful signal that regulators somewhere reviewed a dossier — and the absence of FDA approval, after late-stage US testing, is an equally meaningful one. The review is also written by the peptide's discoverer, which is worth knowing when reading its enthusiasm about emerging applications.
The largest trial: sepsis, and a null result
TESTS was a multicentre, double-blind, placebo-controlled phase 3 trial across 22 centres in China, published in The BMJ in January 2025. 1,106 adults aged 18-85 with sepsis (Sepsis-3 criteria) were randomized 1:1 to subcutaneous thymosin alpha-1 or placebo every 12 hours for seven days; 1,089 were analysed (Wu et al., BMJ 2025).
28-day all-cause mortality was 23.4% (127/542) with thymosin alpha-1 and 24.1% (132/547) with placebo — hazard ratio 0.99 (95% CI 0.77 to 1.27; P=0.93). No secondary or safety outcome differed significantly. Pre-specified subgroup analyses hinted at heterogeneity by age (worse under 60, HR 1.67) and diabetes status (HR 0.58), but subgroup findings from a null trial are hypotheses, not results. The authors' conclusion was that there is no clear evidence thymosin alpha-1 decreases 28-day mortality in sepsis.
This trial matters beyond sepsis: it is the field's best-powered test of the general proposition that boosting T-cell function with this peptide improves hard clinical outcomes in immune-compromised patients.
COVID-19 and other investigational areas
A 2023 review in International Immunopharmacology surveys the respiratory-infection literature and finds it genuinely mixed (Bellet et al.). Retrospective COVID-19 analyses conflicted — one found reduced mortality in severe patients, others found none, and a meta-analysis of 1,498 patients reported no significant correlation between treatment and mortality. Later prospective work was more favourable, including a phase 3 trial reporting reduced mortality in moderate and severe patients and a phase 2 trial showing increased CD4+ counts. For fungal and bacterial pneumonia the evidence is largely mouse models, with human data limited to a six-patient phase I/II study in stem-cell transplant recipients.
Oncology adjuvant use, particularly in hepatocellular carcinoma after resection or embolisation, has been explored in Chinese trials, mostly as pilot studies with survival and recurrence endpoints.
Context and caveats
- Approval abroad reflects a different regulatory standard and often older, smaller trial packages than the FDA requires.
- The immunological rationale is strong and the clinical results are inconsistent — a common pattern for immunomodulators, where the same intervention may help or harm depending on the patient's immune state.
- Several key sources carry sponsor involvement: the TESTS authors disclose grants from the manufacturer of the branded product.
- Trials studied acutely ill hospitalised patients. Nothing here supports use for general immune "boosting" in healthy adults.